Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer
- Authors
- Kim, YS[Kim, Young Saing]; Hong, J[Hong, Junshik]; Sym, SJ[Sym, Sun Jin]; Park, SH[Park, Se Hoon]; Park, J[Park, Jinny]; Cho, EK[Cho, Eun Kyung]; Lee, JH[Lee, Jae Hoon]; Shin, DB[Shin, Dong Bok]
- Issue Date
- Mar-2010
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- FOLFOX-4; Salvage treatment; Stomach neoplasms
- Citation
- CANCER RESEARCH AND TREATMENT, v.42, no.1, pp.24 - 29
- Indexed
- KCI
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 42
- Number
- 1
- Start Page
- 24
- End Page
- 29
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/74886
- DOI
- 10.4143/crt.2010.42.1.24
- ISSN
- 1598-2998
- Abstract
- Purpose This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). Materials and Methods The AGC patients with an ECOG performance status of 0 similar to 1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m(2) on day 1), leucovorin (200 mg/m(2) on days 1 and 2) and 5-fluorouracil (400 mg/m(2) as a bolus and 600 mg/m(2) as a 22-hour infusion on days 1 and 2) every 2 weeks. Results For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1 similar to 12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. Conclusion Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.